945457-84-1
Chemical Structure
LJ-2698
Synonym(s): FM101
- CAS No.: 945457-84-1
- Formula:C16H15Cl2N5O2S
- Molecular Weight:412.29
IUPAC Name: (2R,3R,4S)-2-(2-chloro-6-((3-chlorobenzyl)amino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol
InChIKey: JQUBXCDDRXAMLF-IXPVHAAZSA-N
SMILES: N(CC1=CC(Cl)=CC=C1)C2=C3C(N(C=N3)[C@H]4[C@H](O)[C@H](O)CS4)=NC(Cl)=N2
Biological Activity: LJ-2698 (FM101) is an orally active adenosine A3 receptor (Adenosine A3 Receptor) antagonist. LJ-2698 blocks adenosine A3 receptor-dependent pro-inflammatory JNK, ERK, and NF-κB signaling pathways. LJ-2698 prevents alveolar cavity enlargement, restores pulmonary function, and inhibits matrix metalloproteinase activity and pulmonary cell apoptosis (apoptosis) in mice. LJ-2698 induces mitochondrial dysfunction, necroptosis, and intrinsic apoptosis. LJ-2698 ameliorates renal injury in mice with diabetic nephropathy, and alleviates diet-induced hepatic inflammation and fibrosis. LJ-2698 can be used in the research of emphysema, diabetic nephropathy, and metabolic dysfunction-associated steatotic liver disease[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
LJ-2698 | LJ-2698 (FM101) is an orally active adenosine A3 receptor (Adenosine A3 Receptor) antagonist. LJ-2698 blocks adenosine A3 receptor-dependent pro-inflammatory JNK, ERK, and NF-κB signaling pathways. LJ-2698 prevents alveolar cavity enlargement, restores pulmonary function, and inhibits matrix metalloproteinase activity and pulmonary cell apoptosis (apoptosis) in mice. LJ-2698 induces mitochondrial dysfunction, necroptosis, and intrinsic apoptosis. LJ-2698 ameliorates renal injury in mice with diabetic nephropathy, and alleviates diet-induced hepatic inflammation and fibrosis. LJ-2698 can be used in the research of emphysema, diabetic nephropathy, and metabolic dysfunction-associated steatotic liver disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Boo HJ, et al. LJ-2698, an Adenosine A3 Receptor Antagonist, Alleviates Elastase-Induced Pulmonary Emphysema in Mice. Biomol Ther (Seoul). 2020;28(3):250-258. [Content Brief]
- [2]. Dorotea D, et al. Orally active, species-independent novel A3 adenosine receptor antagonist protects against kidney injury in db/db mice. Exp Mol Med. 2018 Apr 20;50(4):1-14. [Content Brief]
- [3]. Park JS, et al.. A3AR antagonism mitigates metabolic dysfunction-associated steatotic liver disease by exploiting monocyte-derived Kupffer cell necroptosis and inflammation resolution. Metabolism: clinical and experimental. 2025 Mar;164:156114. [Content Brief]
Keywords
